Trending Immunocytokines Market Report 2021-2026 with Top Companies like Pfizer, Roche, Merck, AstraZeneca

The global Immunocytokines market size is projected to grow from 2021 to 2026. The demand for Immunocytokines can be attributed to patient benefits, growth of the manufacturing sector, increasing production and growing capacity in healthcare industry, and healthy growth of pharmaceutical and food & beverage industry in developing countries, are supporting the growth of the Immunocytokines market.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/286964 .

Pandemic impact on the Global Immunocytokines Market:

The declining prices, supply-demand gap, and COVID-19 pandemic impact had severe impact on the Immunocytokines market. Due to the COVID-19 pandemic, the demand for Immunocytokines has been increasing due to rise in the healthcare throughput, suspension of manufacturing activities, disruption of supply chain, and postponement of the expansion projects across the globe. However, during pandemic period, the growing demand from the food & beverage, and pharmaceutical industries supports to offset the marginal decline in demand caused due to slowdown in the manufacturing sector across the globe.

Global Immunocytokines Market Dynamics:

Immunocytokines (ICs) are a class of molecules created by linking tumor-reactive monoclonal antibodies to cytokines that are able to activate immune cells. Immunocytokines have been made and tested by us, and others, using a variety of tumor-reactive mAbs linked to distinct cytokines. Immunocytokines are a novel class of biopharmaceuticals, consisting of a cytokine moiety fused to monoclonal antibodies or to an antibody fragment, which selectively accumulate at the disease site and thereby enhance the therapeutic effects of cytokines.

The report shows market effect factors analysis that precisely emphasizes technology progress/risk, consumer needs/customer preference changes, technology progress in a related industry that draws the growth factors of the market. The evident quantitative as well as qualitative insights about the Global Immunocytokines market are covered in the report along with forecast analysis of all the Global Immunocytokines market that expected to modify the market in the future are described in detail. The segmental analysis also highlights details about different aspects that will influence the market.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Immunocytokines Market Report 2021” @ https://www.businessindustryreports.com/buy-now/286964/single .

Immunocytokines Market Players:

Alkermes Plc
AstraZeneca Plc
CytImmune
Cytune Pharma
Altor Biosciences Corporation
Apeiron Biologics AG
Paladin Labs
Teva Pharmaceutical Industries Ltd.
Valor Biotherapeutics
Targa Therapeutics Corporation
Immunomedics, Inc.
ImmunGene, Inc.
MolMed S.p.A.
Merck KGaA
Nektar Therapeutics
Pfizer, Inc.
F. Hoffmann-La Roche, Ltd.

Product Type Segmentation:

Liver
Hypothalamus
Fat muscle
B and T lymphocytes
Bone Marrow Endothelium

Industry Segmentation:

Tumors and Cancer
Rheumatoid Arthritis

Segmentation by Regions:

On the basis of Regional analysis, North America and Europe holds major share in global Immunocytokines market. Moreover, Asia-Pacific is expected to record higher growth rate in Immunocytokines Market during the forecast year.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/286964 .

Top Industry News:

VALNEVA AND PFIZER ANNOUNCE INITIATION OF PHASE 2 STUDY FOR LYME DISEASE VACCINE CANDIDATE ON 08 MARCH, 2021 -- Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies.

As announced in December 20201, VLA15-221 is a randomized, observer-blind, placebo-controlled Phase 2 study. It will be the first VLA15 study to include a pediatric population (aged 5-17 years). Overall, the study will enroll approximately 600 healthy participants (aged 5-65 years) who will receive VLA15 or placebo. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6).

“We are excited to be part of the Lyme disease vaccine development program with Valneva. We hope this Phase 2 trial, with a simplified schedule, will provide evidence that the investigational vaccine can be used in populations that are at risk of contracting Lyme disease, potentially including children age five years and older,” said Kathrin Jansen, Senior Vice President and Head of Pfizer Vaccine Research and Development.

Juan Carlos Jaramillo, MD, Chief Medical Officer of Valneva commented, “This trial initiation marks an important step in the development of VLA15 toward a potential licensure. Including a pediatric population in Phase 2 means we could, if successful, add this population to the Phase 3 research program, to potentially offer a vaccine for Lyme disease that may help prevent disease in both adults and children, if approved. We are pleased that, together with our partner Pfizer, we have decided to pursue this development while preparing for a potential Phase 3 start.”

Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA152. Under the terms of the agreement, first subject, first dose in this study will trigger a milestone payment of $10 million from Pfizer to Valneva.

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.